ReviewOncology (Williston Park, N.Y.)2012
Malignant pleural mesothelioma: factors influencing the prognosis.
Review in Oncology (Williston Park, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.Scientific reports · 2017Trial
- The role of single nucleotide polymorphisms related to iron homeostasis in mesothelioma susceptibility after asbestos exposure: a genetic study on autoptic samples.Frontiers in public health · 2023Article
- Article
- Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells.Cancers · 2021Article
- Does size matter? -a population-based analysis of malignant pleural mesothelioma.Translational lung cancer research · 2020Article
- Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma.Radiology and oncology · 2018Article
- Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.BMC pulmonary medicine · 2018Article
- Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.OncoTargets and therapy · 2017Article
- Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.Disease markers · 2017Article
- Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.Scientific reports · 2016Article
- HOX transcription factors are potential targets and markers in malignant mesothelioma.BMC cancer · 2016Article
- Clinical significance of serum CA125 in diffuse malignant mesothelioma.SpringerPlus · 2016Article
- The role of interleukin-6 in malignant mesothelioma.Translational lung cancer research · 2015Review
- Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.Radiology and oncology · 2014Article
- Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.Lung · 2014Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a highly severe primary tumor of the pleura mainly related to exposure to asbestos fibers. The median survival after symptom onset is less than 12 months. Conventional medical and surgical therapies--either as single lines or combined--are not wholly effective. No universally accepted guidelines have yet been established for patient selection and the use of therapeutic strategies. In addition, retrospective staging systems have proved inadequate at improving therapeutic outcomes. Therapy is currently guided by gross tumor characteristics and patient features; however, these seem less accurate than the biological fingerprint of the tumor. A number of clinical prognostic factors have been considered in large multicenter series and independently validated. A series of novel biomarkers can predict the evolution of the disease. Here we summarize the principal and novel factors that influence prognosis and are thus potentially useful for selecting patients for targeted therapy.
Indexed as
Identifiers
23413596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.